Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
allergan
3
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
biotech
eli lilly
fda
marc goodman
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
svb leerink
abbvie
alder biopharmaceutical
alkermes
american academy of neurology
amgen
atogepant
biohaven
bob azelby
botox
boulder/denver blog main
boulder/denver top stories
brian abrahams
bristol-myers squibb
buprenorphine
calcitonin gene-related peptide
cariprazine
clinical data
detroit blog main
detroit top stories
drugs
eptinezumab
erenumab
What
drug
3
×
fda
medicine
new
won
alkermes
antipsychotic
approval
approved
arguments
benefits
big
caveats
class
commercialized
commonly
companies
competitors
data
decades
designed
disease
drugs
effect
fatty
favor
gain
horizon
intercept
known
liver
make
marketed
meeting
migraine
nash
neuro
nonalcoholic
offer
oral
Language
unset
Current search:
allergan
×
drug
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
